BCL2 and acute myeloid leukemia: It reduced the expression of both c-MYC and BCL-2 and triggered cell cycle arrest at the G0/G1 phase and apoptosis in AML cells, thus showing a promising example of dual targeting, with activity against signals supporting both proliferation and survival of leukemic cells.